Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 827

Sort by

Sort Order Select

Journal Articles

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Murielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, Karim Belhadj, Salomon Manier, Laurent Garderet, Martine Escoffre-Barbe, Clara Mariette, Lotfi Benboubker, Denis Caillot, Cécile Sonntag, Cyrille Touzeau, Jehan Dupuis, Philippe Moreau, Xavier Leleu, Thierry Facon, Benjamin Hébraud, Jill Corre, Michel Attal

Blood (2021) 138 (2): 113–121.

https://doi.org/10.1182/blood.2021010744

Published: 2021

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2019-132629

Published: 2019

Journal Articles

Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity; The Emerging Role of Autophagy

Panagiotis Efentakis, PhD, Ioanna Andreadou, PhD, Panagiota-Efstathia Nikolaou, PhD, Claudius Witzler, Svenja Siemer, Eftathios Kastritis, Philip Wenzel, MD PhD, Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 3797.

https://doi.org/10.1182/blood-2019-123522

Published: 2019

Journal Articles

Targeting MDM2 and XIAP By Idasanutlin in Diffuse Large B-Cell Lymphoma

Juan J. Gu, MD PhD, Samuel J. Thompson, Cory Mavis, MSc, Matthew J. Barth, MD, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 5301.

https://doi.org/10.1182/blood-2019-129009

Published: 2019

Journal Articles

Bortezomib Overcomes Poor Prognosis Conferred By High Sictp in Untreated Plasma Cell Disorders

Akira Honda, MD PhD, Yu Oyama, MD, Kazuhiro Toyama, MD PhD, Mineo Kurokawa, MD PhD

Blood (2019) 134 (Supplement_1): 5492.

https://doi.org/10.1182/blood-2019-129324

Published: 2019

Journal Articles

Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

Maimoona Khan, MBBS, Asma Waheed, MBBS, Rida Ul Jannat, MBBS, Arafat Ali Ali Farooqui, MD, Muhammad Saad Farooqi, MD, Ali Younas Khan, MD, Madeeha Shafqat, Muhaddis Ejaz Ahmad, MD, Muhammad Abdullah Yousaf, MBBS, MD, Tariq Iqtidar Sadiq Syed, MD, Syed Maaz Abdullah, MBBS, Sravanthi Kotapati, MBBS, Irbaz Riaz, MDMMSc, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5588.

https://doi.org/10.1182/blood-2019-128833

Published: 2019

Journal Articles

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma

Diana Basali, MD, Rajshekhar Chakraborty, MD, Lisa Rybicki, MS, Nathaniel Rosko, PharmD, Janice Reed, RN, Mary Ann Karam, RN, Kristen Schlueter, RN, Hayley Dysert, Beth M. Faiman, PhDCNP, Kimberly Hamilton, APRN/PA, Matt Kalaycio, MD, Jason Valent, MD

Blood (2019) 134 (Supplement_1): 5566.

https://doi.org/10.1182/blood-2019-129002

Published: 2019

Journal Articles

Advancements in Treatment for Newly Diagnosed Frail and Elderly Myeloma Patients: A Systematic Review

Syed Maaz Abdullah, MBBS, Tariq Iqtidar Sadiq Syed, MD, Muhammad Salman Faisal, MD MBBS, Awais Ijaz, MD, Syeda Sabeeka Batool, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Muhammad Abdullah Yousaf, MBBS, MD, Saif Ur Rehman, MBBS, MD, Maaz Ahmed Yusufi, MD, Sravanthi Kotapati, MBBS, Maimoona Khan, MBBS, Asma Waheed, MBBS, Khadija Zia Zaidi, MBBS, Sikander Abdullah, MBBS, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5589.

https://doi.org/10.1182/blood-2019-128892

Published: 2019

Journal Articles

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Shebli Atrash, MD, Myra Robinson, MS, Manisha Bhutani, MD, Jeffrey A. Zonder, Reed Friend, MD, Barry Paul, MD, Daniel Auclair, Jordan Robinsons, Ami P Ndiaye, NP, Kelly Bumgarner, Sarah Norek, James T. Symanowski, PhD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS

Blood (2019) 134 (Supplement_1): 5570.

https://doi.org/10.1182/blood-2019-130290

Published: 2019

Journal Articles

Retrospective Analysis of the Efficacy of Triplet Therapy, Including Lenalidomide, in Newly Diagnosed Multiple Myeloma Patients Who Obtained Responses Less Than VGPR after Rd Therapy

Naoki Takezako, MD PhD, Naoya Kaneko, MD, Airi Hamano, Ph, Kenichi Ito, MD, Naohiro Sekiguchi, MD, Satoshi Noto, MD, Takanori Teshima, MD

Blood (2019) 134 (Supplement_1): 5595.

https://doi.org/10.1182/blood-2019-131617

Published: 2019

Journal Articles

Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

Pallavi Mehta, MD DM, Neha Yadav, BDS , MBA, Mohan Bhaarat, Sumeet Prakash Mirgh, MBBS, MDDM, Vishvdeep Khushoo, MBBS, MDDM, Shinto Francis Thekuddan, MBBS, MDDM, Narendra Agrawal, MD DM, Rayaz Ahmed, MDDM, Dinesh Bhurani, MD DM, FRCPA

Blood (2019) 134 (Supplement_1): 5572.

https://doi.org/10.1182/blood-2019-131674

Published: 2019

Journal Articles

Three Drug Regimens for Newly Diagnosed Multiple Myeloma Transplant-Ineligible Elderly Patients - a Systematic Review

Abdul Aziz Siddiqui, MD, Kazi Najamus-saqib Khan, Arafat Ali Farooqui, MD, Muhammad Saad Farooqi, MD, Muhammad Junaid Tariq, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5574.

https://doi.org/10.1182/blood-2019-132095

Published: 2019

Journal Articles

Infectious Complications Following Venetoclax-Proteasome Inhibitor Based Regimens in Relapsed Myeloma: A Single Center Retrospective Analysis

Christopher Tor Sauter, MD, Luca L Bernabei, BA, Adam Waxman, MD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Dan T. Vogl, MD, Sara Whittington,, RN, MPH, Colleen Harker Erb, CRNP, Patricia Mangan, CRNP, Mary Sanchez, CRNP, Edward A. Stadtmauer, MD FACP

Blood (2019) 134 (Supplement_1): 5598.

https://doi.org/10.1182/blood-2019-132087

Published: 2019

Journal Articles

A Single-Center Retrospective Cohort Analysis of Venetoclax in Relapsed/Refractory Multiple Myeloma

Swetha Kambhampati, MD, Derek Galligan, MD, Guy Ledergor, MD, Thomas G. Martin, III, MD, Jeffrey Wolf, Sandy W. Wong, Nina D. Shah, MD

Blood (2019) 134 (Supplement_1): 5576.

https://doi.org/10.1182/blood-2019-122383

Published: 2019

Journal Articles

An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma

Tim J Peterson, PharmD, Neha Korde, MD, Hani Hassoun, MD, Sham Mailankody, MBBS, Alexander M. Lesokhin, MD, Malin Hultcrantz, MD PhD, Urvi A Shah, MD, Eric L Smith, MD PhD, Sydney X Lu, MD PhD, Heather J Landau, MD, Gunjan L. Shah, MD, Michael Scordo, MD, Oscar B Lahoud, MD, Sergio A Giralt, MD, Ola Landgren, MD PhD

Blood (2019) 134 (Supplement_1): 5554.

https://doi.org/10.1182/blood-2019-124376

Published: 2019

Journal Articles

Updates in Clinical Data on FDA Fast Track Drugs for Relapsed Refractory Multiple Myeloma: A Systematic Review of Literature

Muhammad Abdullah Yousaf, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Maaz Ahmed Yusufi, MD, Asim Tameez ud din, MD, Muhammad Qudrat Ullah, MD, Muhammad Yasir Anwar, MD, Abdul Rafae, MD, Mustafa Nadeem Malik, MD, Zunairah Shah, MBBS, Ahmed Ibrahim, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5579.

https://doi.org/10.1182/blood-2019-123296

Published: 2019

Journal Articles

Patterns of Relapse and Treatment for Relapsed/Refractory AL Amyloidosis: A Systematic Review

Adeela Mushtaq, MD, Hamza Hassan, MD MBBS, Razwana Khanam, MD, Ahmad Iftikhar, MD, Midhat Lakhani, MD, Muhammad Abdullah Yousaf, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Maaz Ahmed Yusufi, MD, Seemal Iftikhar, MD, Aneeqa A Zafar, MD, Irbaz Riaz, MDMMSc, M Hasib Sidiqi, MBBS, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5556.

https://doi.org/10.1182/blood-2019-125148

Published: 2019

Journal Articles

Early Salvage Treatment with Second-Generation Novel Agents at Biochemical Relapse Prolongs Overall Survival: A Real-World Single Center Experience

Uros Markovic, MD, Valerio Leotta, MD, Alessandra Romano, MD PhD, Vittorio Del Fabro, MD, Giuseppe Sapienza, MD, Enrica Antonia Martino, MD, Marina Parisi, MD, Valeria Calafiore, Francesco Di Raimondo, MD, Concetta Conticello, MD

Blood (2019) 134 (Supplement_1): 5530.

https://doi.org/10.1182/blood-2019-130415

Published: 2019

Journal Articles

Treatment with Novel Agents in Patients with Multiple Myeloma in México: Data of Characteristics, Treatment Patterns and Outcomes from a Health Care System

Fernando Pérez-Jacobo, MD, Elia Zamora P., MD, Irma Leticia Barrios-Hernández, MD, Nubia Paloma Pérez-Mar, MD, Lidia Mondragón-Posadas, MD, Patricia Galindo-Delgado, MD, Magdalena Bahena-García, MD, Adrian Hernández-López, MD

Blood (2019) 134 (Supplement_1): 5562.

https://doi.org/10.1182/blood-2019-127582

Published: 2019

Journal Articles

Review of 20 Years Outcome of Multiple Myeloma Novel Agent Era at Samsung Medical Center, a Korean Cancer Center

Sang Eun Yoon, MD, Seok Jin Kim, MD PhD, Kihyun Kim, MD PhD

Blood (2019) 134 (Supplement_1): 5585.

https://doi.org/10.1182/blood-2019-127872

Published: 2019

NARROW

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity; The Emerging Role of Autophagy

Targeting MDM2 and XIAP By Idasanutlin in Diffuse Large B-Cell Lymphoma

Bortezomib Overcomes Poor Prognosis Conferred By High Sictp in Untreated Plasma Cell Disorders

Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma

Advancements in Treatment for Newly Diagnosed Frail and Elderly Myeloma Patients: A Systematic Review

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Retrospective Analysis of the Efficacy of Triplet Therapy, Including Lenalidomide, in Newly Diagnosed Multiple Myeloma Patients Who Obtained Responses Less Than VGPR after Rd Therapy

Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

Three Drug Regimens for Newly Diagnosed Multiple Myeloma Transplant-Ineligible Elderly Patients - a Systematic Review

Infectious Complications Following Venetoclax-Proteasome Inhibitor Based Regimens in Relapsed Myeloma: A Single Center Retrospective Analysis

A Single-Center Retrospective Cohort Analysis of Venetoclax in Relapsed/Refractory Multiple Myeloma

An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma

Updates in Clinical Data on FDA Fast Track Drugs for Relapsed Refractory Multiple Myeloma: A Systematic Review of Literature

Patterns of Relapse and Treatment for Relapsed/Refractory AL Amyloidosis: A Systematic Review

Early Salvage Treatment with Second-Generation Novel Agents at Biochemical Relapse Prolongs Overall Survival: A Real-World Single Center Experience

Treatment with Novel Agents in Patients with Multiple Myeloma in México: Data of Characteristics, Treatment Patterns and Outcomes from a Health Care System

Review of 20 Years Outcome of Multiple Myeloma Novel Agent Era at Samsung Medical Center, a Korean Cancer Center

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only